BridgeMD
New treatment option for Adenoid Cystic Carcinoma
Official title Clinical Trial of HG146 Administered to Participants with Adenoid Cystic Carcinoma
ClinicalTrials.gov ID: NCT06781567
What this study is testing
What is HG146?
HG146 is an investigational medicine, given as a pill taken by mouth, being studied as a potential treatment for adenoid cystic carcinoma.
Also referred to as HG146 Capsule.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This is a Phase II, open-label, non-randomized, multicenter study to evaluate the clinical efficacy and safety of HG146 in participants with recurrent or metastatic adenoid cystic carcinoma. This study is divided into two stages.
- Phase 2: a mid-size study of how well it works
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Signed informed consent form (ICF) and able to comply with study.
- Age ≥18 years, gender unlimited.
- Recurrent or metastatic adenoid cystic carcinoma with evidence of disease progression (imaging progression or clinical evidence of progression)...
- Estimated survival \>12 weeks, as determined by the investigator.
- The United States Eastern Cancer Consortium (ECOG) physical status score 0-1.
You likely can't join if
- Symptomatic central nervous system (CNS) metastases that have required steroids within 4 weeks prior to first dose of study treatment.
- Received prior therapies targeting HDAC.
- Chemotherapy was received within 21 days before the first administration of the study treatment, and anti-tumor therapy such as radiotherapy...
- Used strong CYP3A4 inhibitors or inducers within 7 days before the first use of the investigational drug.
- Major surgery or major injury \<=28 days before the first dose of study treatment,or anticipated major surgery during the study.
- Prior allogeneic bone marrow transplantation or other solid organ transplantation
See the full eligibility criteria
- Signed informed consent form (ICF) and able to comply with study.
- Age ≥18 years, gender unlimited.
- Recurrent or metastatic adenoid cystic carcinoma with evidence of disease progression (imaging progression or clinical evidence of progression) within one year of histological or cytological diagnosis.
- Estimated survival \>12 weeks, as determined by the investigator.
- The United States Eastern Cancer Consortium (ECOG) physical status score 0-1.
- Has adequate organ function.
- At least 1 measurable tumor lesion according to RECISTv1.1 criteria.
- Symptomatic central nervous system (CNS) metastases that have required steroids within 4 weeks prior to first dose of study treatment.
- Received prior therapies targeting HDAC.
- Chemotherapy was received within 21 days before the first administration of the study treatment, and anti-tumor therapy such as radiotherapy, biotherapy, targeted therapy, and immunotherapy was received within 28 days...
- Used strong CYP3A4 inhibitors or inducers within 7 days before the first use of the investigational drug.
- Major surgery or major injury \<=28 days before the first dose of study treatment,or anticipated major surgery during the study.
- Prior allogeneic bone marrow transplantation or other solid organ transplantation
- Active infection requiring systemic treatment.
- Current or past presence of other malignancies (other than adequately treated basal cell or squamous cell carcinoma of the skin and carcinoma in situ of the cervix), unless radical treatment has been performed and there...
- A person is known to be allergic to any active ingredient or excipient of the investigational drug.
- Pregnant or lactating women.
- patients with drug abuse or chronic alcohol abuse that may affect the evaluation of the test results.
The study team makes the final eligibility decision.
Where it's taking place
- Shanghai, Shanghai Municipality, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Shanghai, Shanghai Municipality, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.